scholarly journals Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CA

2021 ◽  
Author(s):  
Shouhua Pan ◽  
Si Li ◽  
Mingzhe Xiao ◽  
Dongsheng Chen ◽  
Junlong Li
Keyword(s):  
Bladder Cancer ◽  
Treatment Options ◽  
Complete Response ◽  
Significant Benefit ◽  
Urothelial Bladder Cancer ◽  
Multiple Tumor ◽  
First Line Therapy ◽  
First Case ◽  
Potential Biomarker ◽  
Urothelial Bladder

Abstract Urothelial bladder cancer (UBC) is a common malignancy with significant mortality worldwide. However, treatment options of UBC were mainly chemotherapy and immunotherapy since few targeted agents had shown efficacy in UBC. In recent studies, everolimus has showed antitumor activity in patients harboring aberrations in PI3K/Akt/mTOR pathway in multiple tumor types. Here we report a patient with metastatic UBC harboring a rare M1043I mutation of PIK3CA detected by DNA based next-generation sequencing. The patient received everolimus as first-line therapy after palliative transurethral resection. Within one months, the residual lymph node metastases achieved complete response and no more ostealgia was reported. To our knowledge, this is the first case reporting a significant benefit from everolimus in PIK3CA mutant UBC, suggesting the rare M1043I mutation variant may be a potential biomarker of sensitivity to everolimus. Further mechanism insights and clinical studies are needed to clarify the effectiveness of everolimus in patients with PIK3CA M1043I mutation.

scholarly journals CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

2019 ◽  
Vol 38 (1) ◽  
Author(s):  
Francesco Morra ◽  
Francesco Merolla ◽  
Daniela Criscuolo ◽  
Luigi Insabato ◽  
Riccardo Giannella ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Options ◽  
High Grade ◽  
Urothelial Bladder Cancer ◽  
Expression Levels ◽  
Novel Treatment ◽  
Urothelial Bladder

scholarly journals Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Franklin C. Lee ◽  
William Harris ◽  
Heather H. Cheng ◽  
Jaideep Shenoi ◽  
Song Zhao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Urothelial Cancer ◽  
Response Rates ◽  
Complete Response ◽  
Pathologic Response ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Alternative Regimen

Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting.Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011. Outcomes of interest included those with complete response (pT0) and any response (≤pT1). Odds ratios were calculated using multivariate logistic regression.Results. Compared to those who did not receive neoadjuvant chemotherapy, there were more patients with complete response (28% versus 9%, OR 3.11 (95% CI: 1.45–6.64),P=0.03) and any response (52% versus 25%, OR 3.23 (95% CI: 1.21–8.64),P=0.01). Seventy-two patients received GC (n=41) or MVAC (n=31). CR was achieved in 29% and 22% of GC and MVAC patients, respectively (multivariate OR 0.39, 95% CI 0.10–1.58). Any response (≤pT1) was achieved in 56% of GC and 45% of MVAC patients (multivariate OR 0.45, 95% CI 0.12–1.71).Conclusions. We observed similar pathologic response rates for GC and MVAC neoadjuvant chemotherapy in this cohort of patients with muscle invasive urothelial cancer (MIBC). Our findings support the use of GC as an alternative regimen in the neoadjuvant setting.

scholarly journals Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer

2019 ◽  
Vol 20 (5) ◽  
pp. 1102 ◽  
Author(s):  
Nada Humayun-Zakaria ◽  
Roland Arnold ◽  
Anshita Goel ◽  
Douglas Ward ◽  
Stuart Savill ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Basic Knowledge ◽  
Urothelial Bladder Cancer ◽  
Cellular Processes ◽  
Non Invasive ◽  
Potential Biomarker ◽  
Urothelial Bladder ◽  
Splice Forms ◽  
Treatment And Diagnosis ◽  
Made In

Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances in treatment and diagnosis have been made in recent years. In this review, we discuss potential biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome. The expression of these genes is tissue-specific. Tropomyosins are responsible for diverse cellular roles, most notably based upon their interplay with actin to maintain cellular processes, integrity and structure. Tropomyosins exhibit a large variety of splice forms, and altered isoform expression levels have been associated with cancer, including UBC. Notably, tropomyosin isoforms are detectable in urine, offering the potential for non-invasive diagnosis and risk-stratification. This review collates the basic knowledge on tropomyosin and its isoforms, and discusses their relationships with cancer-related phenomena, most specifically in UBC.

scholarly journals Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations

2018 ◽  
pp. 1-7 ◽  
Author(s):  
Randy F. Sweis ◽  
Brian Heiss ◽  
Jeremy Segal ◽  
Lauren Ritterhouse ◽  
Sabah Kadri ◽  
...  
Keyword(s):  
Dna Damage ◽  
Bladder Cancer ◽  
Dna Damage Response ◽  
Gene Mutations ◽  
Clinical Activity ◽  
Urothelial Bladder Cancer ◽  
Response Gene ◽  
Damage Response ◽  
Urothelial Bladder

scholarly journals Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer

2018 ◽  
Vol 4 (1) ◽  
pp. 137-137
Author(s):  
Madhuri Koti ◽  
Amanda Shuo Xu ◽  
Kevin Yi Mi Ren ◽  
Kash Visram ◽  
Runhan Ren ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumour Stage ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Tertiary Lymphoid Structures ◽  
Lymphoid Structures
Sign in / Sign up

Export Citation Format

Share Document